NCT02203851View on ClinicalTrials.gov

Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

November 20, 2014

Primary Completion Date

September 4, 2018

Study Completion Date

September 4, 2018

Conditions
Psoriasis
Interventions
DRUG

Risankizumab

Risankizumab administered by subcutaneous (SC) injection

Sponsors

Lead Sponsor

AbbVie

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

AbbVie

INDUSTRY